2026 Annual Meeting of Shareholders
2026 Annual Meeting of Shareholders
Tuesday, May 5, 2026, 10:00 AM ET
Summary of Proceedings
Presiding: Christopher S. Boerner, Ph.D., Board Chair and Chief Executive Officer
Attendance:
A total of 1,773,513,056 shares of the company’s common stock were represented at the meeting in person or by proxy. This attendance constituted approximately 86.86% of the shares outstanding and entitled to vote at the meeting.
Election of the Board of Directors:
Nominated and elected to serve as directors of the company until the 2027 Annual Meeting were Peter J. Arduini, Deepak L. Bhatt, M.D., M.P.H., M.B.A., Christopher S. Boerner, Ph.D., Julia A. Haller, M.D., Manuel Hidalgo Medina, M.D., Ph.D., Michael R. McMullen, Paula A. Price, Derica W. Rice, Theodore R. Samuels, Karen H. Vousden, Ph.D. and Phyllis R. Yale.
Management Proposals:
The management proposal on the advisory vote to approve the compensation of our named executive officers was approved by a vote of 1,459,162,310 shares in favor, with 72,490,026 shares against, 6,933,061 shares abstaining and 234,927,659 broker non-votes.
The company’s 2026 Stock Award and Incentive Plan was approved by a vote of 1,470,672,957 shares in favor, with 63,896,918 shares against, 4,015,522 shares abstaining and 234,927,659 broker non-votes.
The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the company for the year 2026 was ratified by a vote of 1,706,279,839 shares in favor, with 63,727,901 shares against and 3,505,316 shares abstaining.
Shareholder Proposal:
The shareholder proposal on the adoption of a Board policy that the chairperson of the Board be an Independent Director was not approved based upon a vote of 422,069,323 shares in favor, with 1,109,378,680 shares against, 7,137,394 shares abstaining and 234,927,659 broker non-votes.
A replay of the proceedings can be found here: www.virtualshareholdermeeting.com/BMY2026. This replay will remain active for approximately one year following the proceedings.
Materials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations.
In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. The website may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com.